Alpha 1-Antitrypsin Deficiency
Pipeline by Development Stage
Competitive Landscape
8 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 16 trials with date data
Clinical Trials (16)
Total enrollment: 618 patients across 16 trials
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)
A Study of Belcesiran in Patients With AATLD
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency
Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
A Phase 1, First-in-human Study of VX-634
Study of DCR-A1AT in Healthy Adult Volunteers
Study of ARO-AAT in Normal Adult Volunteers
Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency